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Objective: International travelers from non-endemic areas are at high risk of contracting 
malaria due to their lack of immunity. Prevention is therefore of outmost importance and is 
achieved through effective and safe chemoprophylaxis, which reduces the risk of fatal disease. 
Among the various antimalarial drugs available, the synergistic combination of atovaquone 
and proguanil (A/P) (Malarone®; Glaxo-SmithKline) has proven a valuable option in terms 
of effective protection against chloroquine and multi-drug resistant falciparum malaria, 
safety, tolerability, and ease of use, thus favoring compliance. The purpose of the present 
study was to assess acceptability and ease of use of A/P chemoprophylaxis in a population 
of employees of the oil industry bound to malarious areas. Particular attention was paid to 
treatment adherence.
Methods: A survey was conducted on a sample of 700 employees on A/P chemoprophylaxis. 
Demographic data and speciﬁ  c information on A/P treatment were collected by means of a 
16-item questionnaire administered immediately before departure. All questionnaires returned 
were then entered into a database and statistically analyzed.
Results: Both habitual and ﬁ  rst-time travelers showed good adherence to A/P chemoprophylactic 
regimen. In general, only few adverse side-effects were reported, none of which were serious. 
Travelers with previous experience of other antimalarials stated A/P prophylaxis had proven 
advantageous due to fewer adverse reactions, better condition of administration, and better 
sense of protection compared with other available treatments.
Keywords: atovaquone and proguanil, Malarone, malaria prophylaxis, prevention, 
compliance
Introduction
Each year an estimated 50 million travelers visit malaria endemic areas (Schlagenhauf 
et al 2003) and 10,000–30,000 of them fall ill with malaria after returning home 
(Lobel and Kozarsky 1997; WHO 2008). This imported malaria, which represents an 
important public health problem with a high mortality rate (Muentener et at 1999), 
can be easily treated if diagnosed promptly, and it follows a serious course in only 
about 12% of individuals (Croft 2000).
The risk of infection varies considerably, depending on the degree of endemicity, 
the duration of stay, individual behavior, and preventive measures taken (Simons et al 
2005). Risk is especially high in tropical Africa, where 80%–95% of infections are 
caused by Plasmodium falciparum (Steffen et al 2003), the most serious form. Most 
cases of falciparum malaria occur because of poor adherence to or complete failure 
to use chemoprophylaxis, combined with failure to take adequate precautions against 
mosquito bites (WHO 2008).Therapeutics and Clinical Risk Management 2008:4(5) 1106
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Malaria control must be an essential part of health 
care programs provided by companies operating abroad in 
malarious areas. This is especially important considering 
that travelers from malaria-free regions going to endemic 
areas are highly vulnerable as they have little or no immu-
nity, and are often exposed to delayed or wrong diagnosis 
when returning to their home country (WHO 2007).
Many companies have in-house medical depart-
ments providing the necessary assistance. Italian-based 
Saipem, a subsidiary of the Eni Group, is a case in point. 
In compliance with Italian law 626/94, the company has 
implemented a speciﬁ  c program for the prevention and 
control of malaria in the case of workers traveling to or 
residing in high risk endemic areas. Besides receiving pre-
travel educational materials and medical advice, Saipem’s 
personnel are offered chemoprophylactic treatment with 
atovaquone and proguanil hydrochloride (Malarone®; 
Glaxo-SmithKline) as effective chemoprophylactic regi-
men appropriate for subjects bound to malaria-endemic 
destinations. The ﬁ  xed-dose combination of atovaquone 
and proguanil (A/P) has been reported to be highly effec-
tive for prophylaxis of malaria caused by P. falciparum 
(Shanks et al 1998; Boggild et al 2007) having an excel-
lent safety proﬁ  le during both prophylaxis and treatment 
courses (Boggild et al 2007).
In the case of individuals undergoing malaria prophylaxis 
while on duty, it is important that the treatment chosen has 
no negative effects that may interfere with their performance 
With respect to this, the choice of A/P appears to be more 
advantageous compared to other antimalarials such as meﬂ  o-
quine and chloroquine for which severe neuropsychiatric 
disturbances have been reported in approximately 1 in 10,000 
travelers (WHO 2008).
The present study is a questionnaire-based survey that 
was conducted on a sample of healthy travelers to remote 
worksites in malarious areas. The aim was to obtain some 
insights into A/P compliance in the attempt to acquire real-
world data on the acceptability and tolerability of A/P treat-
ment from the traveler’s point of view.
Participants and methods
A total of 700 Saipem’s healthy employees (643 males 
and 57 females) traveling to malaria-endemic areas (Nigeria, 
Republic of the Congo, Angola) in the period from January 
2007 to November 2007 were eligible for inclusion in the 
study. Duration of trip was 7 days on average.
Subjects were consecutively enrolled from a larger 
group of Saipem’s employees who voluntarily agreed to 
participate in the study. Just before departure, all subjects 
underwent clinical examination and referred to the 
Saipem medical department where they received pretravel 
advice on appropriate measures of individual protection, 
chemoprophylaxis, and treatment. In concomitance with 
the counseling, they were administered a paper question-
naire by Saipem’s travel medicine specialist with the aim 
of gathering data on the use, management, and effects of 
A/P chemoprophylaxis.
The questionnaire, which was provided with detailed 
instructions to ensure accurate completion, consisted of 
16 questions to be entered after departure from the malarious 
area. The information requested regarded demographic data 
(age, sex, education), information on personal knowledge 
of malaria prevention/chemoprophylaxis, and possible use 
of antimalarial drugs in the past. The second part included 
questions on A/P chemoprophylaxis: ease of use, adher-
ence to the prescribed regimen, and experience of adverse 
side-effects.
All 700 questionnaires were entered into a database and 
analyzed. Statistical analysis was performed using Student’s 
t-test to compare average data of quantitative variables 
between patients who had either already traveled or were 
traveling for the ﬁ  rst time as Saipem’s employees to a 
malaria-endemic area. Statistical signiﬁ  cance of differences 
in distribution frequency was tested by chi-square test 
(Pearson) and analysis of contingency tables. A p value 
of 0.05 was considered to be statistically signiﬁ  cant. 
Analysis was carried out using statistical package SPSS 
10.0 (SPSS Inc. Chicago).
Results
All 700 travelers completed the questionnaires in all their 
parts for a response rate of 100% and delivered them to 
Saipem’s medical department on their return. Of these, 
85% were returned in electronic form and the remainder 
(15%) on paper. Ninety percent of the respondents were 
habitual travelers, whereas 10% were on their ﬁ  rst visit 
to a malarious region as employees of Saipem. Most were 
male (92%) in both groups. Mean age was 38.3 years in 
the group of habitual travelers and 30.7 in those traveling 
for the ﬁ  rst time. Most had a high educational background: 
tertiary school (22%) or first degree or post-degree 
specialization (77%). Compliance was extremely high as 
99.6% of subjects adhered to the A/P chemoprophylactic 
regimen, which required 1 adult tablet (atovaquone 250 mg + 
proguanil hydrochloride 100 mg) daily beginning 1–2 days 
before exposure, throughout exposure, and continuing 7 days Therapeutics and Clinical Risk Management 2008:4(5) 1107
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after departure from the malaria-endemic area (CDC 2007). 
Only 3 individuals were not compliant, and the reason for 
failing to adhere was explained as low perception of malaria 
exposure risk (Table 1).
Of the habitual travelers, most (88.5%) had used 
chemoprophylaxis with A/P on previous occasions (mean 
number of times 2.4) and for only 72 of them (11.5%) this 
was the ﬁ  rst time they had experienced A/P prophylaxis. 
Nearly all habitual travelers (96.5%) had taken other anti-
malarials on past occasions, namely meﬂ  oquine (67.7%), 
proguanil (12.6%), chloroquine (12.5%), and doxycy-
cline (7.3%). Among ﬁ  rst-time travelers only meﬂ  oquine 
(n = 30; 100%) was indicated as medication previously used 
as an antimalarial (Table 2).
When asked about the reason for choosing A/P as anti-
malarial chemoprophylaxis, 44% of the habitual travelers 
and 59% of ﬁ  rst-time travelers responded that they were 
following medical advice. For an equal proportion in both 
groups (23%) the reason was because they were aware of 
the regimen beneﬁ  ts. Twenty-two percent of the habitual 
travelers compared with about 10% in the other group 
admitted having chosen A/P for the fewer adverse side-
effects. Better sense of protection against the disease was 
the answer chosen by 10 % of habitual travelers against 8% 
of ﬁ  rst-time travelers (Figures 1 and 2).
When asked to highlight possible differences with other 
antimalarial drugs, the group of habitual travelers gener-
ally declared having experienced much fewer (85.2%) or 
rather fewer (14.8%) adverse side-effects. Condition of 
administration was generally well accepted, being very 
easy (5.5%) and rather easy (94.5%) to manage. In terms of 
sense of protection against the disease, most had felt rather 
(77.2%) and much (22.8%) more protected if compared 
with previous other prophylactic treatments (Table 3). The 
most common adverse reaction was abdominal pain in both 
habitual travelers (n = 61) and ﬁ  rst-time travelers (n = 24), 
followed by few cases of headache and nausea. No serious 
adverse reactions were reported (Table 4).
Discussion
Past studies, recently reviewed by Boggild et al (2007) 
have proved A/T efﬁ  cacy and optimum safety proﬁ  le, 
considering also its advantage over other antimalarial 
drugs in terms of efficacy against multidrug-resistant 
P. falciparum malaria.
Our aim, however, was to assess the impact of A/P 
chemoprophylaxis in actual conditions of usage with 
particular attention to ease of use, individual capacity to Therapeutics and Clinical Risk Management 2008:4(5) 1108
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comply with the regimen prescribed, and experience of 
adverse reactions. Of note, the survey was carried out on 
a considerably large sample (n = 700), if compared with 
available studies, whose samples do not usually exceed 
150 included subjects.
Our ﬁ  ndings are in line with other published data for safety 
and tolerability (Shanks et al 1998; Schlagenhauf et al 2003; 
Simons et al 2005), in that A/P prophylaxis was well tolerated, 
with only mild to moderate adverse side-effects – namely, those 
reported by the manufacturer – and no serious adverse reactions. 
We may speculate that the lack of important adverse reactions 
may have favored better adherence to the regimen prescribed as 
shown by the high proportion of travelers who reported regular 
chemoprophylaxis. As noted in a number of studies including 
the paper by Franco-Paredes et al (2006), non-adherence to 
chemoprophylactic regimens is in fact frequently secondary 
to drug side effects. Furthermore, in a study by McKeage 
and Scott (2003) fewer recipients of A/P discontinued treat-
ment because of adverse events than individuals receiving 
chloroquine plus proguanil or meﬂ  oquine. Most importantly, 
no A/P-related neuropsychiatric disturbances were reported. 
These ﬁ  ndings reﬂ  ect those of previous studies demostrating 
a lower frequency of neuropsychiatric adverse events with A/P 
compared with meﬂ  oquine (Overbosch et al 2001). Considering 
that approximately 1 in 10,000 travelers receiving meﬂ  oquine 
or chloroquine prophylaxis experience severe neuropsychiatric 
disturbances (WHO 2008), our results suggest that A/P may 
be considered a valuable therapeutic option especially when 
treatment concerns subjects on duty where physical and mental 
ﬁ  tness is a prerequisite for their safety (Simons et al 2005).
Table 2 History of chemoprophylaxis in study population
Habitual traveler First-time traveler Total
N % Mean SD N % Mean SD N % Mean SD p
Is this the ﬁ  rst time 
you used A/P?
No
Yes
555
72
88.5
11.5
73 100.0 555
145
79.3
20.7
0.0001
If no, how many times did 
you use A/P in the past?
2.4 1.28 2.4 1.28
Did you use other 
antimalarials other than 
A/P in previous occasions?
Yes 605 96.5 30 42.3 635 91.0
0.0001
No 22 3.5 41 57.8 63 9.0
If yes, specify which ones Meﬂ  oquine 409 67.7 30 100.0 626 68.7
0.0001 
Proguanil 76 12.6 111 12.2
Chloroquine 76 12.5 110 12.1
 Doxycycline 44 7.3             64 7.0    
Abbreviation: A/P,  atovaquone/proguanil combination.
Habitual traveler
44%
24%
22%
10%
Medical advice Awareness of benefits
Fewer adverse side-effects Higher sense of protection 
Figure 1 Reasons underlying preference for atovaquone/proguanil chemoprophylaxis 
in habitual travelers.
First-time traveler
59%
23%
10%
8%
Medical advice Awareness of benefits
Fewer adverse side-effects Higher sense of protection
Figure 2 Reasons underlying preference for atovaquone/proguanil chemoprophylaxis 
in ﬁ  rst-time travelers.Therapeutics and Clinical Risk Management 2008:4(5) 1109
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Compared with other available antimalarial drugs, 
prophylaxis with A/P appears to have appreciable advan-
tages in terms of administration schedule and duration 
of recommended treatment. This aspect may also have 
favored the good level of adherence recorded. In fact, A/P 
prophylaxis can be started only 1–2 days before exposure 
and, above all, since the drug has casual prophylactic 
activity against the hepatic stages of P. falciparum 
(Shapiro et al 1999), it can be discontinued 7 days after 
departing a malarious region (Shanks et al 1999), com-
pared with 4 weeks with other antimalarials. This more 
convenient dosage regimen, particularly in the post-travel 
period, should not be undervalued, considering that good 
chemoprophylaxis does reduce the risk of fatal disease 
(WHO 2008) especially in non-immune or semi-immune 
subjects when they return to their home country and that 
adherence rates for 4 weeks post exposure are generally 
low (CDC 2007).
Though it is noteworthy that the survey was conducted 
on a large sample, it is necessary to point out some 
limitations that suggest cautious interpretation of the ﬁ  ndings 
observed.
Treatment adherence was found to be very high (99%), 
which was probably the result of an overestimation 
because of the method employed. Questionnaire assess-
ment, though widely used, has in fact some limitations 
because returning travelers tend to forget precise date and 
time of drug intake and over-report the correct regimen in 
an effort to please the investigator or to hide one’s failure 
(Landry et al 2006).
As for the side effects reported, it must be noted that 
monitoring was focused more on acute events, since 
questionnaires were delivered on return from the endemic 
area. As a consequence, under-reporting is likely to have 
occurred, especially on adverse reactions that emerged 
after some period of time. Moreover, it was not possible to 
assess possible interactions with other drugs as no speciﬁ  c 
medical data were collected from the sample. A further 
limitation is that our study lacks a control group using a 
different chemoprophylaxis and that most subjects included 
were male.
Nonetheless, data gathered from such a large number of 
subjects may be helpful in providing new insights into the 
real acceptability of A/P chemoprophylaxis. In the future it 
would be worth investigating further its good tolerability 
proﬁ  le and more convenient dosage regimen in well-designed 
studies to prove their value in promoting better adherence 
and thus better efﬁ  cacy.
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